EP3773576A4 - Liants de céréblon pour la dégradation d'ikaros - Google Patents
Liants de céréblon pour la dégradation d'ikaros Download PDFInfo
- Publication number
- EP3773576A4 EP3773576A4 EP19777205.6A EP19777205A EP3773576A4 EP 3773576 A4 EP3773576 A4 EP 3773576A4 EP 19777205 A EP19777205 A EP 19777205A EP 3773576 A4 EP3773576 A4 EP 3773576A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- ikaros
- degradation
- cereblon
- binders
- cereblon binders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 title 1
- 102000017182 Ikaros Transcription Factor Human genes 0.000 title 1
- 108010013958 Ikaros Transcription Factor Proteins 0.000 title 1
- 102100032783 Protein cereblon Human genes 0.000 title 1
- 239000011230 binding agent Substances 0.000 title 1
- 230000015556 catabolic process Effects 0.000 title 1
- 238000006731 degradation reaction Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862648238P | 2018-03-26 | 2018-03-26 | |
| PCT/US2019/024094 WO2019191112A1 (fr) | 2018-03-26 | 2019-03-26 | Liants de céréblon pour la dégradation d'ikaros |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3773576A1 EP3773576A1 (fr) | 2021-02-17 |
| EP3773576A4 true EP3773576A4 (fr) | 2021-12-29 |
Family
ID=68060453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19777205.6A Withdrawn EP3773576A4 (fr) | 2018-03-26 | 2019-03-26 | Liants de céréblon pour la dégradation d'ikaros |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11753397B2 (fr) |
| EP (1) | EP3773576A4 (fr) |
| JP (1) | JP2021519337A (fr) |
| KR (1) | KR20210018199A (fr) |
| CN (1) | CN111902141A (fr) |
| WO (1) | WO2019191112A1 (fr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4483875A3 (fr) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Dégronimères spirocycliques pour la dégradation de protéines cibles |
| EP3641762B1 (fr) | 2017-06-20 | 2026-02-18 | C4 Therapeutics, Inc. | Dégrons et dégronimères à liaison n/o pour la dégradation de protéines |
| EP3679028A1 (fr) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydroquinolinones |
| EP3679026A1 (fr) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimide |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| WO2019204354A1 (fr) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Composés spirocycliques |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CU20210002A7 (es) * | 2018-07-10 | 2021-08-06 | Novartis Ag | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2) |
| US12459921B2 (en) | 2018-09-30 | 2025-11-04 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Isoindoline compound, preparation method, pharmaceutical composition and use thereof |
| EP3896062A4 (fr) * | 2018-12-06 | 2022-06-15 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Composé d'isoindoline, procédé de préparation, composition pharmaceutique et utilisation du composé d'isoindoline |
| WO2020128972A1 (fr) * | 2018-12-20 | 2020-06-25 | Novartis Ag | Schéma posologique et combinaison pharmaceutique comprenant des dérivés de 3-(1-oxoisoindoline-2-yl) pipéridine-2,6-dione |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| MA55628A (fr) | 2019-04-12 | 2022-02-16 | C4 Therapeutics Inc | Agents de dégradation tricycliques d'ikaros et d'aiolos |
| KR20220103753A (ko) * | 2019-11-19 | 2022-07-22 | 브리스톨-마이어스 스큅 컴퍼니 | 헬리오스 단백질의 억제제로서 유용한 화합물 |
| ES2980575T3 (es) * | 2019-12-18 | 2024-10-02 | Novartis Ag | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos |
| EP4681715A3 (fr) | 2019-12-20 | 2026-01-28 | C4 Therapeutics, Inc. | Composés d'isoindolinone et d'indazole pour la dégradation de l'egfr |
| IL295709A (en) | 2020-03-05 | 2022-10-01 | C4 Therapeutics Inc | Compounds for targeted degradation of brd9 |
| TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
| WO2021222542A1 (fr) * | 2020-04-30 | 2021-11-04 | President And Fellows Of Harvard College | Dérivés de 5-amino-2-pipéridinon-3-yl-1-oxoisoindoline pour la dégradation des agents de dégradation ikzf2 |
| CA3173629A1 (fr) | 2020-06-19 | 2021-12-13 | Cosimo Dolente | Agents de degradation de braf |
| EP4192458A4 (fr) | 2020-08-05 | 2024-09-04 | C4 Therapeutics, Inc. | Composés pour la dégradation ciblée de ret |
| IL300373A (en) * | 2020-08-07 | 2023-04-01 | C4 Therapeutics Inc | Beneficial treatments for disorders mediated by IKAROS or AIOLOS |
| JP2024515545A (ja) * | 2021-04-05 | 2024-04-10 | ブリストル－マイヤーズ スクイブ カンパニー | がん治療のためのピリジニル置換オキソイソインドリン化合物 |
| PT4320112T (pt) * | 2021-04-06 | 2025-07-07 | Bristol Myers Squibb Co | Compostos de oxoisoindolina substituídos por piridinilo |
| MX2023014547A (es) * | 2021-06-23 | 2024-04-29 | Hoffmann La Roche | Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3). |
| US20250129047A1 (en) | 2021-07-04 | 2025-04-24 | Newave Pharmaceutical Inc. | Isoquinoline derivatives as mutant egfr modulators and uses thereof |
| CN113603630B (zh) * | 2021-08-10 | 2023-06-27 | 苏州小栗医药科技有限公司 | 一种4-苯基哌啶盐酸盐的合成方法 |
| EP4493554A1 (fr) * | 2022-03-17 | 2025-01-22 | Gilead Sciences, Inc. | Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations |
| CN117088864B (zh) * | 2022-05-13 | 2026-03-03 | 广州智药生物科技有限公司 | 一种苯并[d]异恶唑类化合物及其应用 |
| CA3249074A1 (fr) * | 2022-06-06 | 2023-12-14 | C4 Therapeutics, Inc. | Liants de céréblon de glutarimide à substitution bicyclique |
| IL317668A (en) * | 2022-06-16 | 2025-02-01 | Prelude Therapeutics Inc | KAT6-targeted compounds with a ubiquitin ligase-binding residue |
| CN117285524A (zh) * | 2022-06-24 | 2023-12-26 | 中国科学院上海药物研究所 | 一类取代的4-氨基异吲哚啉类化合物、其制备方法、药物组合物及应用 |
| JP2025531869A (ja) | 2022-09-09 | 2025-09-25 | イノヴォ セラピューティクス、インコーポレイテッド | ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物 |
| WO2024073507A1 (fr) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Composés macrocycliques et leurs utilisations |
| WO2024140637A1 (fr) * | 2022-12-27 | 2024-07-04 | 标新生物医药科技(上海)有限公司 | Dérivé de pipéridinedione à substitution oxoisoindolinyle et son utilisation |
| EP4735438A2 (fr) | 2023-06-30 | 2026-05-06 | Merck Patent GmbH | Composés hétérobifonctionnels pour la dégradation de kras |
| AU2024310341A1 (en) | 2023-06-30 | 2026-02-12 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
| AU2024344247A1 (en) | 2023-09-19 | 2026-05-07 | Kancure Pte. Ltd. | Survivin-targeted compounds |
| WO2025179161A1 (fr) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Composés de dégradation de protéines |
| US20250333407A1 (en) * | 2024-04-29 | 2025-10-30 | Bristol-Myers Squibb Company | Compounds and Their Use for Treatment of Hemoglobinopathies |
| WO2026035974A1 (fr) * | 2024-08-09 | 2026-02-12 | Triana Biomedicines, Inc. | Dégradeurs de la kinase du lymphome anaplasique (alk) et leurs utilisations |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150291562A1 (en) * | 2014-04-14 | 2015-10-15 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
Family Cites Families (204)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| GB9322014D0 (en) | 1993-10-26 | 1993-12-15 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| SE9401108D0 (sv) | 1994-03-31 | 1994-03-31 | Leiras Oy | Ophthalmic composition I |
| SE9401109D0 (sv) | 1994-03-31 | 1994-03-31 | Leiras Oy | Opthalmic composition II |
| GB9412273D0 (en) | 1994-06-18 | 1994-08-10 | Univ Nottingham | Administration means |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| US6413539B1 (en) | 1996-10-31 | 2002-07-02 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| GB9515182D0 (en) | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| DE69717160T2 (de) | 1996-09-13 | 2003-05-08 | Mitsubishi Pharma Corp., Osaka | Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen |
| US20010006973A1 (en) * | 1998-03-16 | 2001-07-05 | Hon-Wah Man | 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels |
| US6045501A (en) | 1998-08-28 | 2000-04-04 | Celgene Corporation | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
| GB9827145D0 (en) | 1998-12-09 | 1999-02-03 | Co Ordinated Drug Dev | Improvements in or relating to powders |
| US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
| US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
| EP1279406A4 (fr) | 2000-04-03 | 2007-10-24 | Santen Pharmaceutical Co Ltd | Transporteurs et systeme de distribution de medicament les utilisant |
| GB0009469D0 (en) | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
| GB0009468D0 (en) | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
| US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| PT1913939T (pt) | 2000-06-27 | 2017-07-19 | Vectura Ltd | Formulações para utilização em dispositivos inalatórios |
| GB2364919A (en) | 2000-07-21 | 2002-02-13 | Cambridge Consultants | Inhalers |
| US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| EP1322750A4 (fr) | 2000-09-08 | 2004-09-29 | California Inst Of Techn | Medicament chimere de ciblage de proteolyse |
| US6315720B1 (en) | 2000-10-23 | 2001-11-13 | Celgene Corporation | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
| AU2000202A (en) | 2000-10-31 | 2002-05-15 | Pr Pharmaceuticals Inc | Methods and compositions for enhanced delivery of bioactive molecules |
| AU2002220857A1 (en) | 2000-11-30 | 2002-06-11 | Vectura Limited | Particles for use in a pharmaceutical composition |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| DE60309887T2 (de) | 2002-07-30 | 2007-05-16 | Novartis Ag | Kombination von einem aromatasehemmer mit einem bisphosphonat |
| US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US7230012B2 (en) | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
| US20050009910A1 (en) | 2003-07-10 | 2005-01-13 | Allergan, Inc. | Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug |
| NZ545484A (en) | 2003-09-15 | 2009-09-25 | Vectura Ltd | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation |
| JP2007505932A (ja) | 2003-09-18 | 2007-03-15 | マクサイト， インコーポレイテッド | 経強膜送達 |
| GB0407627D0 (en) | 2004-04-02 | 2004-05-05 | Vectura Ltd | Corkscrew pump |
| ES2246694B1 (es) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Nanoparticulas pegiladas. |
| US8512738B2 (en) | 2004-04-30 | 2013-08-20 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase implants |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| WO2006086750A1 (fr) | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Formulations liquides pour le traitement de maladies ou affections |
| US8999289B2 (en) | 2005-03-22 | 2015-04-07 | President And Fellows Of Harvard College | Treatment of protein degradation disorders |
| MX2007016039A (es) | 2005-06-17 | 2008-10-27 | Univ North Carolina | Metodos, sistemas y materiales de fabricacion de nanoparticulas. |
| US20070071756A1 (en) | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Delivery of an agent to ameliorate inflammation |
| US20070178133A1 (en) | 2005-11-09 | 2007-08-02 | Liquidia Technologies, Inc. | Medical device, materials, and methods |
| WO2007081876A2 (fr) | 2006-01-04 | 2007-07-19 | Liquidia Technologies, Inc. | Surfaces nanostructurées pour applications biomédicales/biomatérielles et traitements à partir de celles-ci |
| WO2007084418A2 (fr) | 2006-01-13 | 2007-07-26 | Surmodics, Inc. | Matrices contenant des microparticules pour l'administration de médicaments |
| CN101443004B (zh) | 2006-03-23 | 2013-03-06 | 参天制药株式会社 | 用于与血管通透性有关的疾病或病症的制剂 |
| US20080166411A1 (en) | 2006-04-10 | 2008-07-10 | Pfizer Inc | Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles |
| WO2007133808A2 (fr) | 2006-05-15 | 2007-11-22 | Liquidia Technologies, Inc. | Nanoparticules pour applications cosmétiques |
| CL2007002218A1 (es) | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| NZ575061A (en) | 2006-08-30 | 2011-10-28 | Celgene Corp | 5-substituted isoindoline compounds |
| WO2008033567A1 (fr) | 2006-09-15 | 2008-03-20 | Celgene Corporation | Composés n-méthylaminométhylisoindole, compositions les contenant et leurs procédés d'utilisation |
| LT2420498T (lt) | 2006-09-26 | 2017-10-25 | Celgene Corporation | 5-pakeistieji chinazolinono dariniai, kaip priešvėžiniai agentai |
| WO2008100304A2 (fr) | 2006-11-15 | 2008-08-21 | The University Of North Carolina At Chapel Hill | Composite de particules polymères comportant des particules qui présentent une forme, une taille et un ordre de haute fidélité |
| AU2008229383B2 (en) | 2007-03-20 | 2013-09-05 | Celgene Corporation | 4'-O-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| WO2008122038A1 (fr) | 2007-04-02 | 2008-10-09 | President And Fellows Of Harvard College | Autophagie régulatrice |
| ES2523925T3 (es) | 2007-09-26 | 2014-12-02 | Celgene Corporation | Derivados de quinazolinona sustituidos en posición 6, 7 u 8 y composiciones que los contienen y métodos de uso de los mismos |
| US8476260B2 (en) | 2007-12-28 | 2013-07-02 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
| US20090203709A1 (en) | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor |
| US9943401B2 (en) | 2008-04-04 | 2018-04-17 | Eugene de Juan, Jr. | Therapeutic device for pain management and vision |
| US8945527B2 (en) | 2008-04-25 | 2015-02-03 | The University Of North Carolina At Chapel Hill | Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates |
| WO2009132206A1 (fr) | 2008-04-25 | 2009-10-29 | Liquidia Technologies, Inc. | Compositions et procédés pour administration et libération intracellulaire de chargement |
| US20090298882A1 (en) | 2008-05-13 | 2009-12-03 | Muller George W | Thioxoisoindoline compounds and compositions comprising and methods of using the same |
| WO2010009087A1 (fr) | 2008-07-15 | 2010-01-21 | Eyegate Pharmaceuticals, Inc. | Administration iontophorétique d'une formulation à libération contrôlée dans l'œil |
| EP2358697B1 (fr) | 2008-10-29 | 2015-10-21 | Celgene Corporation | Composés d'isoindoline utilisables dans le cadre du traitement du cancer |
| KR101880582B1 (ko) | 2008-12-05 | 2018-07-20 | 리퀴디아 테크놀로지스 인코포레이티드 | 패턴 재료 제조 방법 |
| CA3045436C (fr) | 2009-01-29 | 2025-10-07 | Forsight Vision4, Inc. | Administration d'un medicament dans le segment posterieur |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| US20120052041A1 (en) | 2009-02-04 | 2012-03-01 | The Brigham And Women's Hospital, Inc. | Polymeric nanoparticles with enhanced drug-loading and methods of use thereof |
| US8192408B2 (en) | 2009-02-10 | 2012-06-05 | Psivida Us, Inc. | Ocular trocar assembly |
| KR101674904B1 (ko) | 2009-02-26 | 2016-11-10 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 중재형 약물전달 시스템과 그 방법 |
| WO2010107485A1 (fr) | 2009-03-17 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | Inhibiteurs de ligase e3 |
| US10952965B2 (en) | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
| AU2010249615B2 (en) | 2009-05-19 | 2013-07-18 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
| AU2010256558B2 (en) | 2009-06-03 | 2013-10-03 | Forsight Labs, Llc | Anterior segment drug delivery |
| WO2011008737A2 (fr) | 2009-07-13 | 2011-01-20 | The University Of North Carolina At Chapel Hill | Particules d'aérosol modifiées et procédés associés |
| US9556426B2 (en) | 2009-09-16 | 2017-01-31 | Celgene Avilomics Research, Inc. | Protein kinase conjugates and inhibitors |
| US9498385B2 (en) | 2009-10-23 | 2016-11-22 | Nexisvision, Inc. | Conformable therapeutic shield for vision and pain |
| WO2011050327A1 (fr) | 2009-10-23 | 2011-04-28 | Forsight Labs Llc | Insensibilisation des nerfs de la cornée en vue de traiter la douleur oculaire |
| MX336731B (es) | 2010-01-28 | 2016-01-28 | Harvard College | Composiciones y metodos para potenciar la actividad de proteasoma. |
| US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| WO2011097218A1 (fr) | 2010-02-02 | 2011-08-11 | Wayne State University | Agents thérapeutiques anticancéreux |
| WO2011109384A2 (fr) | 2010-03-02 | 2011-09-09 | Allergan, Inc. | Polymères biodégradables dans la diminution de la pression intra-oculaire |
| MX384074B (es) | 2010-05-14 | 2025-03-12 | Dana Farber Cancer Inst Inc | Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos. |
| HUE033581T2 (hu) | 2010-06-10 | 2017-12-28 | Seragon Pharmaceuticals Inc | Ösztrogén receptor modulátorok és alkalmazásaik |
| EP2588129A4 (fr) | 2010-06-30 | 2014-07-09 | Univ Brandeis | Dégradation des protéines ciblées par de petites molécules |
| WO2012019136A2 (fr) | 2010-08-05 | 2012-02-09 | Forsight Vision 4, Inc. | Appareil d'injection et procédé d'administration de médicament |
| WO2012019047A2 (fr) | 2010-08-05 | 2012-02-09 | Forsight Vision4, Inc. | Implant sous-conjonctival pour une administration d'un médicament dans le segment postérieur |
| CN103209664A (zh) | 2010-08-05 | 2013-07-17 | 弗赛特影像4股份有限公司 | 可植入的治疗装置 |
| CN103153316B (zh) | 2010-08-05 | 2015-08-19 | 弗赛特影像4股份有限公司 | 组合药物递送方法和设备 |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| US20140033800A1 (en) | 2010-11-11 | 2014-02-06 | Forsight Vision4, Inc. | Methods and apparatus to determine diffusion properties of porous structures for drug delivery |
| TW201304822A (zh) | 2010-11-15 | 2013-02-01 | Vectura Ltd | 組成物及用途 |
| AU2011329656B2 (en) | 2010-11-19 | 2017-01-05 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| AU2011338615B2 (en) | 2010-12-07 | 2017-07-27 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
| WO2012079022A1 (fr) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Dérivés de dioxopipéridinylphtalimide substitué |
| BRPI1100318A2 (pt) | 2011-02-18 | 2013-05-21 | Univ Estadual Paulista Jelio De Mesquita Filho | processo de obtenÇço de compostos derivados derivados de anti-inflamatàrios esteràides (aies), composiÇÕes farmacÊuticas contendo tais compostos e seus usos no tratamento de doenÇas de carÁter inflamatàrio. |
| CA2840380A1 (fr) | 2011-06-24 | 2012-12-27 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs selectifs de l'isoforme 6 de l'histone desacetylase et procedes associes |
| RU2740680C2 (ru) | 2011-09-14 | 2021-01-19 | Форсайт Вижн5, Инк. | Глазное вкладочное устройство и способы |
| SI2755600T1 (sl) | 2011-09-16 | 2021-08-31 | Forsight Vision4, Inc. | Naprava za izmenjavo tekočine |
| JP6254088B2 (ja) | 2011-10-17 | 2017-12-27 | バイオセリックス， インコーポレイテッド | 置換ビアリールアルキルアミド |
| US20150037428A1 (en) | 2011-11-29 | 2015-02-05 | The University Of North Carolina At Chapel Hill | Geometrically engineered particles and methods for modulating macrophage or immune responses |
| DK2797652T3 (en) | 2011-12-27 | 2019-03-11 | Vectura Gmbh | FEEDBACK SYSTEM INHALATION DEVICE |
| WO2013106646A2 (fr) | 2012-01-12 | 2013-07-18 | Yale University | Composés et procédés pour l'inhibition de l'ubiquitine ligase vcb e3 |
| JP2015508414A (ja) | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法 |
| US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
| PL2846859T3 (pl) | 2012-03-09 | 2017-07-31 | Vectura Gmbh | Kanał mieszania do urządzenia do inhalacji i urządzenie do inhalacji |
| US20140107025A1 (en) | 2012-04-16 | 2014-04-17 | Jade Therapeutics, Llc | Ocular drug delivery system |
| US20150119435A1 (en) | 2012-05-11 | 2015-04-30 | Yale University | Compounds useful for promoting protein degradation and methods using same |
| AU2013315125B2 (en) | 2012-09-17 | 2018-07-26 | Pfizer Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
| WO2014047439A1 (fr) | 2012-09-20 | 2014-03-27 | Akina, Inc. | Microcapsules biodégradables contenant une matière de charge |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| EP2911623B1 (fr) | 2012-10-26 | 2019-08-14 | Forsight Vision5, Inc. | Système ophtalmique pour la libération prolongée de médicament dans l' oeil |
| PT2724741T (pt) | 2012-10-26 | 2017-08-02 | Vectura Gmbh | Dispositivo de inalação para uso em terapia por aerossol |
| KR102229478B1 (ko) | 2012-11-01 | 2021-03-18 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료 |
| JP2016512846A (ja) | 2013-03-13 | 2016-05-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｒａｓ阻害剤およびその使用 |
| AU2014236455B2 (en) | 2013-03-14 | 2018-07-12 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| JP6280573B2 (ja) | 2013-03-14 | 2018-02-14 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | ブロモドメイン阻害薬としてのフロピリジン |
| JP2016520532A (ja) | 2013-03-15 | 2016-07-14 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | ベンゾイミダゾール誘導体およびその使用 |
| AU2014241163B2 (en) | 2013-03-28 | 2018-09-27 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
| ES2834964T3 (es) | 2013-04-01 | 2021-06-21 | Allergan Inc | Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida |
| CN103421061A (zh) | 2013-08-14 | 2013-12-04 | 中国药科大学 | 来那度胺衍生物、其制法及其医药用途 |
| CA2927321A1 (fr) | 2013-10-15 | 2015-04-23 | Forsight Vision5, Inc. | Preparations et methodes permettant d'augmenter ou de reduire le mucus |
| CA2932120C (fr) * | 2013-12-06 | 2023-09-19 | Celgene Corporation | Methodes de determination de l'efficacite pharmacologique du traitement du lymphome diffus a grandes cellules b, du myelome multiple et des cancers myeloides |
| EP3076948B1 (fr) | 2013-12-06 | 2020-11-18 | Allergan, Inc. | Implant intra-camérulaire pour le traitement d'une pathologie oculaire |
| WO2015085234A1 (fr) | 2013-12-06 | 2015-06-11 | Forsight Vision4, Inc. | Dispositifs thérapeutiques implantables |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US20160022642A1 (en) | 2014-07-25 | 2016-01-28 | Yale University | Compounds Useful for Promoting Protein Degradation and Methods Using Same |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| WO2016065139A1 (fr) | 2014-10-24 | 2016-04-28 | Fl Therapeutics Llc | Pipéridine-2, 6-diones 3-substitués et complexes non-covalents avec l'albumine |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP6815318B2 (ja) * | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| HK1245791A1 (zh) | 2015-01-20 | 2018-08-31 | 阿尔维纳斯运营股份有限公司 | 用於雄激素受体的靶向降解的化合物和方法 |
| GB201504314D0 (en) | 2015-03-13 | 2015-04-29 | Univ Dundee | Small molecules |
| JP7269731B2 (ja) | 2015-03-18 | 2023-05-09 | アルビナス・オペレーションズ・インコーポレイテッド | 標的タンパク質の分解向上のための化合物および方法 |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2016191178A1 (fr) | 2015-05-22 | 2016-12-01 | Biotheryx, Inc. | Protéines de ciblage de composés, compositions, méthodes, et leurs utilisations |
| KR20240119196A (ko) | 2015-06-04 | 2024-08-06 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드계 조절인자 및 관련된 이용 방법 |
| WO2016197114A1 (fr) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs et procédés d'utilisation associés |
| WO2017007612A1 (fr) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles |
| CN108137507A (zh) | 2015-07-10 | 2018-06-08 | 阿尔维纳斯股份有限公司 | 基于mdm2的蛋白水解调节剂和相关的使用方法 |
| CA2988436A1 (fr) | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Modulateurs de proteolyse a base d'alanine et procedes d'utilisation associes |
| AU2016301196B2 (en) | 2015-08-06 | 2022-09-08 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation |
| WO2017024317A2 (fr) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles |
| EP3337476A4 (fr) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Composés et procédés pour la dégradation ciblée de protéines contenant un bromodomaine |
| AU2016349781A1 (en) | 2015-11-02 | 2018-05-10 | Yale University | Proteolysis targeting chimera compounds and methods of preparing and using same |
| CA3017740A1 (fr) | 2016-03-16 | 2017-09-21 | Pearlie BURNETTE | Petites molecules dirigees contre le cereblon pour ameliorer la fonction des lymphocytes t effecteurs |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| AU2017246453A1 (en) | 2016-04-06 | 2018-11-08 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| JP7037500B2 (ja) | 2016-04-06 | 2022-03-16 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Ｍｄｍ２タンパク質分解剤 |
| AU2017250076B2 (en) | 2016-04-12 | 2021-07-22 | The Regents Of The University Of Michigan | Bet protein degraders |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| WO2017197056A1 (fr) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles |
| EP4483875A3 (fr) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Dégronimères spirocycliques pour la dégradation de protéines cibles |
| EP3455219A4 (fr) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | Dégronimères de c3-glutarimide liés à une amine pour la dégradation de protéines cibles |
| US11883381B2 (en) | 2016-05-12 | 2024-01-30 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
| WO2017201069A1 (fr) | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Dérivés d'oxoindoline utilisés comme modulateurs de la fonction protéique |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| CA3032136A1 (fr) | 2016-07-28 | 2018-02-01 | Mayo Foundation For Medical Education And Research | Activateurs de petites molecules de la fonction enzymatique de la parkine |
| CN110062759B (zh) | 2016-09-13 | 2022-05-24 | 密执安大学评议会 | 作为bet蛋白降解剂的稠合的1,4-氧氮杂䓬 |
| ES2857743T3 (es) | 2016-09-13 | 2021-09-29 | Univ Michigan Regents | 1,4-diazepinas fusionadas como degradadores de proteína BET |
| GB2554071A (en) | 2016-09-14 | 2018-03-28 | Univ Dundee | Small molecules |
| ES2975558T3 (es) | 2016-09-15 | 2024-07-09 | Arvinas Inc | Derivados de indol como degradantes de receptor de estrógeno |
| LT3660004T (lt) | 2016-10-11 | 2023-06-12 | Arvinas Operations, Inc. | Junginiai ir metodai, skirti tikslinei androgeno receptoriaus degradacijai |
| EP3535265A4 (fr) | 2016-11-01 | 2020-07-08 | Arvinas, Inc. | Protacs ciblant la protéine tau et méthodes d'utilisation associées |
| WO2018085247A1 (fr) | 2016-11-01 | 2018-05-11 | Cornell University | Composés pour la dégradation de malt1 |
| WO2018102725A1 (fr) | 2016-12-01 | 2018-06-07 | Arvinas, Inc. | Dérivés de tétrahydronaphtalène et de tétrahydroisoquinoléine en tant qu'agents de dégradation des récepteurs des œstrogènes |
| AU2017382176A1 (en) | 2016-12-21 | 2019-05-30 | Biotheryx, Inc. | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
| RU2019121527A (ru) | 2016-12-23 | 2021-01-15 | Эрвинэс Оперейшнс, Инк. | Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения |
| EP3559006A4 (fr) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | Composés et procédés pour la dégradation ciblée de polypeptides de kinase du foie f tal |
| EP3558994A4 (fr) | 2016-12-23 | 2021-05-12 | Arvinas Operations, Inc. | Composés et methodes pour la dégradation ciblée de polypeptides de fibrosarcome rapidement accéléré |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| MX2019008934A (es) | 2017-01-26 | 2019-11-05 | Arvinas Operations Inc | Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,. |
| EP3577109A4 (fr) | 2017-01-31 | 2020-11-18 | Arvinas Operations, Inc. | Ligands de céréblon et composés bifonctionnels les contenant |
| WO2018169777A1 (fr) | 2017-03-14 | 2018-09-20 | Biotheryx, Inc. | Protéines de ciblage de composés, compositions, procédés et utilisations associées |
| US12012467B2 (en) | 2017-03-28 | 2024-06-18 | Regents Of The University Of Michigan | Small molecule DCN1 inhibitors and therapeutic methods using the same |
| US10500194B2 (en) | 2017-04-10 | 2019-12-10 | The Regents Of The University Of Michigan | Covalent small molecule DCN1 inhibitors and therapeutic methods using the same |
| US11261179B2 (en) | 2017-04-14 | 2022-03-01 | University Of Dundee | Small molecules |
| JP7258009B2 (ja) | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| WO2019060693A1 (fr) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | Ligands crbn et utilisations de ces derniers |
| JP7366031B2 (ja) | 2017-09-22 | 2023-10-20 | カイメラ セラピューティクス， インコーポレイテッド | タンパク質分解剤およびそれらの使用 |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| EP3746135A4 (fr) | 2018-01-30 | 2022-03-09 | Foghorn Therapeutics Inc. | Procédés et composés pour traiter des troubles |
| CA3090417A1 (fr) | 2018-02-23 | 2019-08-29 | Dana-Farber Cancer Institute, Inc. | Petites molecules permettant d'induire une degradation selective de proteines et utilisations associees |
| EP3774772A1 (fr) | 2018-04-13 | 2021-02-17 | Arvinas Operations, Inc. | Ligands de céréblon et composés bifonctionnels les contenant |
| EP3787747A4 (fr) | 2018-04-30 | 2022-01-12 | Dana-Farber Cancer Institute, Inc. | Agents de dégradation à petites molécules de polybromo-1 (pbrm1) |
| WO2020006262A1 (fr) | 2018-06-29 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Nouveaux modulateurs du crbn |
| AU2019294836B2 (en) | 2018-06-29 | 2024-06-20 | Dana-Farber Cancer Institute, Inc. | Bispecific degraders |
| WO2020006264A1 (fr) | 2018-06-29 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Ligands pour cereblon (crbn) |
| EP3817822A4 (fr) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | Agents de dégradation de protéines et leurs utilisations |
| WO2020023851A1 (fr) | 2018-07-26 | 2020-01-30 | Yale University | Pyrimidines substituées bifonctionnelles en tant que modulateurs du protéolyse de fak |
| US11707452B2 (en) | 2018-08-20 | 2023-07-25 | Arvinas Operations, Inc. | Modulators of alpha-synuclein proteolysis and associated methods of use |
| IL319737A (en) | 2018-09-07 | 2025-05-01 | Arvinas Operations Inc | Polycyclic compounds and methods for targeted reduction of rapidly accelerating fibrosarcoma polypeptides |
| CN113412259B (zh) | 2018-10-15 | 2024-07-16 | 紐力克斯治疗公司 | 通过泛素蛋白酶体途径降解btk的双官能化合物 |
-
2019
- 2019-03-26 KR KR1020207030739A patent/KR20210018199A/ko not_active Ceased
- 2019-03-26 JP JP2020552829A patent/JP2021519337A/ja not_active Ceased
- 2019-03-26 EP EP19777205.6A patent/EP3773576A4/fr not_active Withdrawn
- 2019-03-26 WO PCT/US2019/024094 patent/WO2019191112A1/fr not_active Ceased
- 2019-03-26 CN CN201980022526.0A patent/CN111902141A/zh active Pending
-
2020
- 2020-09-24 US US17/031,550 patent/US11753397B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150291562A1 (en) * | 2014-04-14 | 2015-10-15 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
Non-Patent Citations (2)
| Title |
|---|
| ROK FRLAN ET AL: "Evaluation of US 2016/0115161 A1: isoindoline compounds and methods of their use", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 27, no. 6, 5 May 2017 (2017-05-05), GB, pages 637 - 641, XP055672236, ISSN: 1354-3776, DOI: 10.1080/13543776.2017.1322954 * |
| RUCHELMAN ALEXANDER L ET AL: "Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 23, no. 1, 1 January 2013 (2013-01-01), pages 360 - 365, XP028961553, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2012.10.071 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021519337A (ja) | 2021-08-10 |
| EP3773576A1 (fr) | 2021-02-17 |
| CN111902141A (zh) | 2020-11-06 |
| WO2019191112A1 (fr) | 2019-10-03 |
| US11753397B2 (en) | 2023-09-12 |
| KR20210018199A (ko) | 2021-02-17 |
| US20210009559A1 (en) | 2021-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3803740A4 (fr) | Protection de chaîne de blocs | |
| EP3868764A4 (fr) | Composé agoniste de sting | |
| AU2019361253A1 (en) | Anti-synuclein antibodies | |
| EP3904108B8 (fr) | Cartouche | |
| EP4238777B8 (fr) | Cartouche | |
| EP3834079A4 (fr) | Configuration à réponses multiples et à questions multiples | |
| EP3904111B8 (fr) | Cartouche | |
| HK40044810A (en) | Cereblon binders for the degradation of ikaros | |
| HK40060479A (zh) | 抗btla抗体 | |
| HK40054305A (en) | Anti-klrg1 antibodies | |
| HK40046591A (en) | Anti-tigit antibodies | |
| HK40041749A (en) | Anti-il36r antibodies | |
| HK40057190A (en) | Novel methods | |
| HK40057188A (en) | Novel methods | |
| HK40042692A (en) | Il-11ra antibodies | |
| HK40051048A (en) | Novel compounds | |
| HK40046106A (zh) | 抗体 | |
| AU2018101027A4 (en) | PadPay | |
| HK40050415A (zh) | 尿流计 | |
| HK40039563A (en) | Cryosphere | |
| AU2018904605A0 (en) | Novel methods | |
| HK1255442B (en) | Seismocardiography | |
| HK1255442A1 (en) | Seismocardiography | |
| AU2018904244A0 (en) | sparemate | |
| AU2018903905A0 (en) | Accuglove |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20201009 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40044810 Country of ref document: HK |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20211129 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 37/00 20060101ALI20211123BHEP Ipc: A61P 35/00 20060101ALI20211123BHEP Ipc: A61P 29/00 20060101ALI20211123BHEP Ipc: C07D 405/14 20060101ALI20211123BHEP Ipc: C07D 413/14 20060101ALI20211123BHEP Ipc: C07D 451/00 20060101ALI20211123BHEP Ipc: C07D 401/04 20060101ALI20211123BHEP Ipc: C07D 401/14 20060101ALI20211123BHEP Ipc: C07D 209/44 20060101ALI20211123BHEP Ipc: A61K 31/454 20060101ALI20211123BHEP Ipc: A61K 31/445 20060101ALI20211123BHEP Ipc: A61K 31/4439 20060101AFI20211123BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20230524 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230528 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20231205 |